Even Bangladesh, according to Reuters, is paying an average of $4 per dose supplied by SII. The report then casts a shadow over how SII in Pune, which is merely
Adar Poonawalla
Covishield, India's first COVID-19 vaccine is approved, safe, effective and ready for roll-out in the coming weeks, said SII CEO Adar Poonawalla on Sunday.
